A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): A first-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent dosed once daily on days 1, 2, 3, and 4 of a 21-day cycle.

Abstract

e13005 Background: The high-affinity folate receptor alpha is selectively overexpressed in some epithelial tumors, including ovarian, endometrial, renal, and breast, and in a few nonepithelial neop...